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A series of recent studies has established the orexin/hypocretin system as a critical 
regulator of sleep/wake states. Its deficiency results in the sleep disorder narcolepsy in 
humans, dogs, and rodents. These findings have brought about the possibility of novel 
therapies for sleep disorders including narcolepsy and insomnia. Moreover, 
accumulating evidence indicates that the orexin/hypocretin system regulates sleep and 
wakefulness through interactions with neuronal systems that regulate emotion, reward, 
and energy homeostasis. Here, we briefly summarize the progress of orexin/hypocretin 








Since its discovery in 1998, the field of orexin/hypocretin biology is continuing to 
expand. Discovery of orexin/hypocretin peptides led to elucidation of an unexpected 
causal relationship between deficiency of the orexin/hypocretin system and the human 
sleep disorder narcolepsy, which brought about a huge impact on the study of sleep and 
wakefulness. Subsequent studies further expanded orexin/hypocretin biology beyond 
the field of sleep/wakefulness, shedding light on the integrative role of the 
orexin/hypocretin system. In parallel, attempts to apply orexin/hypocretin biology to 
clinical areas have led to the development of a novel and definite diagnosis of 
narcolepsy, and are further making progress towards novel treatments for sleep-related 
disorders. 
 Because details of every aspect of orexin/hypocretin biology will be discussed 
in the following chapters, we will here overview the lines of research on 
orexin/hypocretin biology, and further discuss its still unanswered questions and future 
directions. 
 
Discovery of orexin/hypocretin 
 
Completely different approaches taken by two independent laboratories beautifully 
converged on the identification of orexin/hypocretin peptides in 1998. de Lecea et al. 
utilized molecular biological techniques (de Lecea et al., 1998). They had previously 
isolated a series of cDNA clones that are expressed in the hypothalamus but not in the 
cerebellum and the hippocampus by subtractive hybridization. One of these was 
expressed exclusively by a bilaterally symmetric structure within the posterior lateral 
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hypothalamus. They subsequently cloned cDNAs covering the entire coding region, 
which encodes a putative secretory protein of 130 amino acids. According to its primary 
sequence, this protein was predicted to produce two peptide products that are 
structurally related to each other. Since these predicted peptides were expressed in the 
hypothalamus and the authors thought these peptides had similarity to secretin, they 
named them hypocretin-1 and -2, although orexins/hypocretins later turned out not to be 
relatives of the incretin family. Antibodies raised against prepro-hypocretin identified 
hypocretin-positive cell bodies exclusively in the perifornical area of the hypothalamus 
and hypocretin-positive nerve fibers in many brain areas. It was further demonstrated 
that hypocretin is in synaptic vesicles by electron microscopy, and that hypocretin-2 has 
excitatory effects on hypothalamic neurons by electrophysiological study. Thus, their 
study suggested that hypocretin peptides are novel neurotransmitters exclusively 
expressed in a population of neurons in the perifornical area. 
Around the same time as the report by de Lecea et al., Sakurai et al. reported 
identification of novel neuropeptides, termed orexin-A and orexin-B, as endogenous 
ligands of two orphan G-protein coupled receptors (GPCRs whose cognate ligands have 
not been identified, named orexin receptor 1: OX1R and orexin receptor 2: OX2R) 
(Sakurai et al., 1998). These peptides are cleaved from a common single precursor 
polypeptide, prepro-orexin, and are expressed by a particular population of neurons 
clustered around the lateral hypothalamus. It turned out later that prepro-orexin is 
identical to prepro-hypocretin and that orexin-A and -B correspond to hypocretin-1 and 
-2, respectively, although the original predicted structures of hypocretin-1 and -2 were 
not identical to purified orexin-A and -B because of incorrect prediction of proteolytic 
sites, as well as loss of two intrachain disulfate bonds and N-terminal pyroglutamylation 
 MM&TS 5
in hypocretin-1, which were found in orexin-A. 
Since these peptides were exclusively expressed in the lateral hypothalamus, 
which has been known as the “feeding center”, intracerebroventricular (ICV) 
administration of orexin-A or -B was performed to observe the action of these peptides 
on feeding behavior. Orexins are found to increase food intake in rats in a 
dose-dependent manner; this was the reason these peptides were named “orexin” after 
the Greek word orexis, which means appetite. Furthermore, like other mRNAs encoding 
orexigenic peptides such as neuropeptide Y, expression of prepro-orexin mRNA was 
up-regulated more than two-fold upon fasting. 
 
Loss of orexin signaling causes narcolepsy 
 
Soon after the discovery of orexin, two independent studies utilizing dog forward 
genetics and mouse reverse genetics unveiled the causal relationship between orexin 
deficiency and narcolepsy. 
Human narcolepsy is a debilitating neurological disease characterized by 
excessive daytime sleepiness (an insurmountable urge to sleep), which often results in 
falling asleep at inappropriate times and situations (“sleep attacks”), premature 
transitions to REM sleep (so called “sleep-onset REM periods”), and cataplexy (sudden 
bilateral skeletal muscle weakness without impairment of consciousness) (Bassetti and 
Aldrich, 1996). A Stanford University group has established and maintained canine 
breeds with autosomal recessive inheritance of a narcolepsy syndrome for decades. In 
1999, Lin et al. identified mutations in the OX2R gene responsible for canine 
narcolepsy by positional cloning (Lin et al., 1999). 
Around the same time, Chemelli et al. reported that prepro-orexin knockout 
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mice exhibit a phenotype strikingly similar to human narcolepsy, characterized by 
cataplexy-like abrupt behavioral arrests, fragmentation of wakefulness and non-REM 
sleep, characterized by very short wakefulness and NREM sleep episode durations, and 
direct transitions from wakefulness to REM sleep (Chemelli et al., 1999). Consistent 
with a presumed critical role of orexin in sleep/wake regulation, orexin-immunoreactive 
nerve terminals were observed on neurons implicated in arousal regulation, such as the 
locus coeruleus (LC) noradrenergic neurons, raphe serotonergic neurons, 
tuberomammillary nucleus (TMN) histaminergic neurons, and pedunculopontine 
tegmental nucleus/laterodorsal tegmental nucleus (PPT/LDT) and basal forebrain 
cholinergic neurons. Additionally, orexin receptor subtypes are expressed in these 
regions with different expression patterns (Marcus et al., 2001; Mieda et al., 2011). 
Subsequently, deficiency of orexin neurons in human narcolepsy was 
confirmed and reported by three laboratories in 2000. Nishino et al. found that orexin-A 
was undetectable in the cerebrospinal fluid (CSF) of seven out of nine narcolepsy 
patients, but readily detected in normal control individuals (Nishino et al., 2000). 
Peyron et al. and Thannickal et al. further reported marked reductions of orexin mRNA 
and immunoreactivity in postmortem brains of narcolepsy patients (Peyron et al., 2000; 
Thannickal et al., 2000). Furthermore, an unusually severe, early onset case of human 
narcolepsy was associated with a mutation in the orexin gene that impairs peptide 
trafficking and processing (Peyron et al., 2000). 
These studies of humans and animals collectively established that failure of 
signaling mediated by orexin neuropeptides causes narcolepsy. 
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Orexin neurons as stabilizer of sleep/wakefulness states 
 
Even before the discovery of linkage between orexin and narcolepsy, anatomical and 
pharmacological studies had suggested the involvement of these peptides in 
sleep/wakefulness regulation (Peyron et al., 1998; Hagan et al., 1999). After this 
epoch-making discovery, a whole series of studies confirmed that the orexin system 
plays a central role in the regulation of sleep/wakefulness. Neurons expressing orexin 
(orexin neurons) activate nuclei considered wake-promoting, including LC 
noradrenergic neurons (Horvath et al., 1999; van den Pol et al., 2002), raphe 
serotonergic neurons (Brown et al., 2001; Liu et al., 2002), TMN histaminergic neurons 
(Bayer et al., 2001; Yamanaka et al., 2002), and PPT/LDT and basal forebrain 
cholinergic neurons (Eggermann et al., 2001; Eriksson et al., 2001). Central 
administration of orexin-A in rodents reduces REM and non-REM sleep, and increases 
wakefulness time (Hagan et al., 1999). 
 Microinjections of orexin directly into the LC (Bourgin et al., 2000), TMN 
(Huang et al., 2001), BF cholinergic area (Espana et al., 2001), LDT (Xi et al., 2001), 
and lateral preoptic area (Methippara et al., 2000) has arousal effects similar to those of 
ICV injection on sleep/wakefulness states. Recent optogenetic and pharmacogenetic 
manipulations of orexin neurons established a definite causal relation between their 
neuronal activities and transitions of sleep/wakefulness states (Adamantidis et al., 2007; 
Sasaki et al., 2011; Tsunematsu et al., 2011). 
 Although these data suggest that activation of orexin neurons is sufficient to 
promote and maintain wakefulness, their roles in the transitions between wakefulness 
and sleep in natural, physiological conditions still remain unclear. 
 In vivo single unit recordings by three laboratories revealed activity patterns 
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of orexin neurons across sleep/wakefulness cycles in rats and mice with high temporal 
resolution (Lee et al., 2005; Mileykovskiy et al., 2005; Takahashi et al., 2008). 
Essentially, orexin neurons fired most actively during active waking, showed decreased 
discharge during quiet waking, were virtually silent during NREM sleep, and were 
almost silent but exhibited occasional firing during REM sleep. During the transition 
from sleep to wakefulness, orexin neurons fired prior to the onset of EEG activation. 
However, it remains unknown whether orexin neurons initiate awake episodes, or other 
wakefulness-promoting neurons activate orexin neurons. Considering the facts that 
narcoleptics can be roused from sleep and their daily amount of wakefulness is 
relatively similar to that in normal controls, the latter case may be more likely. 
On the other hand, the fact that orexin neurons are much more active during 
active wakefulness than during quiet wakefulness in vivo clearly suggests that the roles 
of orexin extend beyond mere global arousal (Lee et al., 2005; Mileykovskiy et al., 
2005). Consistently, a recent study implicated orexin in central vestibular motor control 
(Zhang et al., 2011). Further examination of context-dependent firing patterns of orexin 
neurons is needed. 
 Narcolepsy is characterized by the inability to maintain wakefulness states, 
pathological intrusion of REM sleep into wakefulness, and frequent transitions between 
states of sleep and wakefulness (Bassetti and Aldrich, 1996), which suggests that 
orexins inhibit inappropriate transition between each vigilance state. This action could 
play important roles in the maintenance and stabilization of sleep and wakefulness. 
 The sleep/wake cycle is thought to be regulated by the balance between the 
sleep-center (sleep-active neurons in the ventrolateral preoptic area have been suggested 
as its correlate) and wake-center (wake-active monoaminergic neurons in the 
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hypothalamus and brain stem have been suggested as its correlate), which reciprocally 
inhibit each other constituting a “flip-flop” circuit (Saper et al., 2001; Sakurai, 2007). In 
this type of circuit, when activity on either side begins to overcome the other, the 
system will flip to one of two possible extremes. Although it is well suited to avoiding 
intermediate states, a small perturbation of the activity on one side can easily cause 
abrupt switching between the two states, resulting in frequent state transitions. Such a 
condition resembles the narcoleptic phenotype. Orexin neurons are likely to function as 
a stabilizer of this circuit by enhancing the activity of monoaminergic neurons during 
wakefulness on demand, avoiding state instability caused by small perturbations 
(Sakurai, 2007). 
 
Integrative physiology of orexin system 
 
In addition to sleep/wakefulness regulation, early descriptions of the projection patterns 
of orexin neurons had already suggested their involvement in a wide range of other 
physiological functions, such as feeding, autonomic regulation, and neuroendocrine 
regulation (Peyron et al., 1998; Date et al., 1999). Consistently, central administration of 
orexin causes a wide variety of effects (Sakurai, 2007). 
The physiological implications of the orexin system are still continuing to 
spread, placing orexin neurons as a link between the arousal center and many other 
systems. 
 As mentioned above, orexins were initially characterized as orexigenic 
peptides (Sakurai et al., 1998). An important difference in the effects on feeding 
between orexin and other orexigenic factors, such as NPY and melanin-concentrating 
hormone (MCH), is that orexin increases both food intake and energy expenditure 
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(Lubkin and Stricker-Krongrad, 1998; Hara et al., 2001), while other feeding peptides 
generally decrease energy expenditure (Spiegelman and Flier, 2001): the latter response 
is more adaptive to conserving energy under food scarcity. Increased energy expenditure 
by orexin administration seems to be caused by increased wakefulness and locomotor 
activity, as well as an increase in sympathetic outflow. Indeed, orexin deficiency 
decreases sympathetic tone (Kayaba et al., 2003; Zhang et al., 2006), resulting in 
reduced energy expenditure. This may explain why human and mouse narcolepsy are 
associated with an increase of body weight despite hypophagia (Lammers et al., 1996; 
Schuld et al., 2000; Hara et al., 2001). Additionally, a recent work suggested that orexin 
enhances leptin-sensitivity through an OX2R-mediated mechanism (Funato et al., 
2009). 
Thus, orexin neurons do not simply act as a system that maintains long-term 
body weight homeostasis. Rather, they seem to be necessary for food seeking and 
feeding behavior, especially when animals are faced with food scarcity. Food seeking 
and food intake require vigilant states which require high energy expenditure. Recent 
evidence suggests that orexin neurons are capable of sensing indicators of energy 
balance and are activated under negative energy balance, such as decreased extracellular 
glucose level, reduced leptin level (an anorexigenic protein hormone secreted by 
adipocytes), and increased ghrelin level (a stomach-derived orexigenic peptide) 
(Yamanaka et al., 2003; Burdakov et al., 2005). Recently, non-essential amino acids 
were also reported to activate orexin neurons, which may potentially benefit an animal 
under prolonged starvation where a rise in extracellular amino acid levels occurs as 
proteins are broken down for fuel (Karnani et al., 2011). 
When faced with a negative energy balance due to reduced food availability, 
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mammals respond behaviorally with phases of increased wakefulness and alertness, 
which presumably enhances their ability to find food. We previously demonstrated that 
orexin neuron-ablated mice are incapable of this fasting-induced arousal, indicating that 
orexin neurons are necessary for evoking adaptive behavioral arousal during fasting 
(Yamanaka et al., 2003). Coordinated increases of sympathetic and 
hypothalamic-pituitary-adrenal (HPA) tone in response to fasting-induced arousal 
directed by orexin neurons may further help animals to execute adaptive behavior. 
Orexin neurons are likely to promote arousal and regulate autonomic and 
endocrine systems according also to water balance, by responding to the antidiuretic 
hormone arginine vasopressin (Tsunematsu et al., 2008), and acid-base homeostasis, by 
sensing changes in pH directly (Williams et al., 2007). 
In this context, emotional states may be another factor through which orexin 
neurons sense and regulate the internal environment accordingly to wake up and 
execute behaviors. Especially under salient conditions, animals exhibit increased 
arousal and vigilance levels, accompanied by increased sympathetic outflow and HPA 
axis activity. Orexin neurons are likely to be involved in the coordinated regulation of 
these responses in stressful environments (Kayaba et al., 2003; Winsky-Sommerer et al., 
2004; Zhang et al., 2006). Furthermore, the orexin system has been also implicated in 
analgesia. Especially, the corticotropin-releasing factor (CRF) and nociceptin/orphanin 
FQ (N/OFQ) systems modulate orexin neurons in a coordinated manner to regulate 
stress-induced analgesia, a key component of the defensive behavioral “fight or flight” 
response (Xie et al., 2008). 
The roles of orexin neurons in the reward system have been a focus of recent 
attention. Dopaminergic projections of neurons in the midbrain ventral tegmental area 
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(VTA) to the forebrain, particularly to the nucleus accumbens (NAc), have classically 
been identified as the “reward pathway”. Drugs of abuse stimulate this pathway, and 
orexin neurons have reciprocal connections with both the VTA and NAc. Orexin 
signaling has been reported to be critical for morphine-induced place preference and 
hyperlocomotion, and reinstatement of extinguished drug-seeking behavior in mice and 
rats (Harris et al., 2005; Narita et al., 2006). Notably, narcolepsy patients with daytime 
sleepiness who were treated with amphetamine-like stimulants and/or GHB for a long 
time rarely developed drug addiction (Guilleminault et al., 1974). These observations 
indicate a strong functional interaction between the orexinergic pathways and the 
dopaminergic system in the mechanisms of reward and drug addiction. This interaction 
may underlie the hedonic control of feeding, as well as the facilitating role of orexin in 
male sexual behavior of rats (Muschamp et al., 2007). 
On the other hand, Boutrel et al. reported that orexin-A/hypocretin-1 
reinstates cocaine seeking by mechanisms different from increased dopamine release, 
rather through induction of a stress-like state (Boutrel et al., 2005). Thus, precise 
consideration of the interactions among the orexin, reward, and stress systems would be 
important. Nevertheless, these findings highlight the key role of orexin in the 
mechanisms of reward and drug addiction. 
Thus, the reciprocal interactions between orexin neurons and multiple 
neuronal systems raise the possibility that orexin neurons function as an interface 
between multiple regulatory systems including feeding, reward, emotional, autonomic, 
and endocrine systems (Fig. 1). This notion is further supported by recent systematic 
searches of afferent pathways to orexin neurons (Sakurai et al., 2005; Yoshida et al., 
2006). Understanding the connectome of orexin neurons more precisely might provide 
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further insights into how the systems regulating emotion, energy homeostasis and 
reward interact with the mechanism that regulates sleep and wakefulness. Further 
precise mechanisms of actions of these peptides could be elucidated by studies 
dissecting the roles of each orexin receptor in particular brain regions, with the aid of 
brain region-specific deletion of orexin receptor genes, as well as brain region-specific 
rescue of receptor expression in narcoleptic orexin receptor knockout mice. In addition, 
the detailed mechanisms underlying context-dependent regulation of orexin neurons 
would be revealed by analyses of mutant mice in which receptors for signaling 





The low CSF orexin-A level in patients with narcolepsy led to the 
development of a novel, definitive diagnostic test for this disease (Mignot et al., 2002). 
Currently, a low orexin-A level in CSF (less than 110 pg/ml) is one of the diagnostic 
criteria for narcolepsy according to the 2nd edition of the International Classification of 
Sleep Disorders (American Academy of Sleep Medicine, 2005). 
In addition, the discovery of a causal link between loss of orexin signaling 
and human narcolepsy has brought about the possibility of novel therapies for this 
disease. Currently, excessive sleepiness is treated using psychostimulants, while 
cataplexy is treated with tricyclic antidepressants (Zeitzer et al., 2006). γ
-hydroxybutyrate (sodium oxybate, GHB) is also used to consolidate nocturnal sleep 
and reduce cataplexy. This therapeutic regimen is problematic due to limited 
effectiveness, undesirable side effects such as insomnia or symptom rebound, and the 
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potential for abuse. We demonstrated that orexin neuron-ablated mice, the most accurate 
pathophysiological murine model of narcolepsy available (Hara et al., 2001), retain the 
ability to respond to ICV administration of orexin neuropeptides, with stabilization of 
wake episodes and prevention of cataleptic attacks (Mieda et al., 2004), suggesting that 
orexin receptor agonists would be of potential value for treating human narcolepsy. 
Conversely, orexin receptor antagonists might be useful as safe hypnotics. 
Indeed, Almorexant (ACT078573, Actelion Pharmaceuticals Ltd.), an orally available 
antagonist of both receptors, has been reported to increase subjective and objective 
electrophysiological signs of sleep in humans (Brisbare-Roch et al., 2007). 
Suvorexant (MK4305, Merck & Co., Inc.) is another compound with potent 
dual orexin receptor antagonistic activity (Cox et al., 2010). This compound is currently 
under Phase IIIb clinical trials for the treatment of primary insomnia. Recently, 
administration of an OX2R selective antagonist, JNJ10397049, in rats was reported to 
be more potent than the dual antagonist almorexant to decrease the latency for persistent 
sleep and increase NREM sleep time (Dugovic et al., 2009). Thus, selective OX2R 
antagonists may offer a possible advantage for the treatment of insomnia. 
Orexin initially drew attention as a regulator of food intake. Therefore, several 
pharmaceutical companies developed orexin receptor antagonists to control appetite for 
obesity treatment. Indeed, an OX1R-selective antagonist, SB334867, reduced food 
intake and ameliorated obesity in leptin-deficient ob/ob mice (Haynes et al., 2002). 
As described above, orexin mediates many behaviors associated with drug 
addiction in rodents owing to its effects on the VTA. A recent report showed that the 
orexin-1 receptor antagonist SB334867 reduces the acquisition and expression of 
cocaine-conditioned reinforcement and the expression of amphetamine-conditioned 
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reward, suggesting that OX1R antagonists have potential as a treatment for individuals 
struggling with drug relapse and dependency (Hutcheson et al., 2011), although whether 
the effects of orexin are the same in humans needs to be confirmed. This notion is 
supported by the fact that drug addiction is seldom found in narcolepsy patients who are 
treated with psychostimulants (Guilleminault et al., 1974). 
OX1R antagonists might also be effective for panic disorders. They inhibit the 
increased mean arterial pressure, heart rate and freezing responses in rat models of 
panic disorder (Johnson et al., 2010). 
We still do not know well why there is specific degeneration of orexin 
neurons in narcolepsy. Narcolepsy has been speculated to be an autoimmune disease 
because of its strong association with certain HLA alleles, which was revealed when the 
causal relationship of the orexin system with this disease was not known, suggesting 
that narcolepsy may result from selective autoimmune degeneration of orexin neurons 
(Kadotani et al., 1998). Recently, Tribbles homolog 2 (Trib2) was reported as a possible 
antigen involved in the autoimmune destruction of orexin neurons (Cvetkovic-Lopes et 
al., 2010). Recent studies also showed that susceptibility to narcolepsy is associated 
with SNPs in the T-cell receptor alpha locus (Hallmayer et al., 2009) and between the 
carnitine palmitoyl-transferase 1B and choline kinase  loci (Miyagawa et al., 2008). 
Understanding the molecular and genetic mechanisms underlying degeneration of 
orexin neurons in the development of narcolepsy would lead to accurate estimation of 




Figure 1. Orexin neurons function as an interface between multiple regulatory systems 
including feeding, reward, emotional, autonomic, and endocrine systems. Orexin 
neurons in the lateral hypothalamic area (LHA) and posterior hypothalamus (PH) are 
anatomically well placed to provide a link between the limbic system, systems involved 
in energy homeostasis, and wakefulness-promoting monoaminergic neurons in the brain 
stem. Solid arrows show excitatory projections, and broken lines inhibitory projections. 
Orexin neurons promote wakefulness through monoaminergic nuclei that are 
wake-active. Stimulation of dopaminergic centers by orexins can modulate reward 
systems. Peripheral metabolic signals such as leptin, ghrelin and glucose influence 
orexin neuronal activity to coordinate arousal and energy homeostasis. The nucleus 
suprachiasmaticus (SCN), the central body clock, sends signals to orexin neurons via 
the dorsomedial hypothalamus (DMH). Input from the limbic system (amygdala and 
bed nucleus of the stria terminalis (BST)) might regulate the activity of orexin neurons 
upon presentation of emotional stimuli that evoke emotional arousal or fear-related 
responses. Orexin neurons also control sympathetic outflow and the neuroendocrine 
system according to the arousal state. VLPO, ventrolateral preoptic area; DR, dorsal 
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